Abstract

PurposeThe main purpose of this study was to understand how the positron emission tomography (PET) measure of the synaptic vesicle 2A (SV2A) protein varies in vivo during the development of temporal lobe epilepsy (TLE) in the kainic acid rat model.ProceduresTwenty Sprague Dawley male rats were administered with multiple systemic doses of saline (control group, n = 5) or kainic acid (5 mg/kg/injection, epileptic group, n = 15). Both groups were scanned at the four phases of TLE (early, latent, transition, and chronic phase) with the [18F]UCB-H PET radiotracer and T2-structural magnetic resonance imaging. At the end of the scans (3 months post-status epilepticus), rats were monitored for 7 days with electroencephalography for the detection of spontaneous electrographic seizures. Finally, the immunofluorescence staining for SV2A expression was performed.ResultsControl rats presented a significant increase in [18F]UCB-H binding at the last two scans, compared with the first ones (p < 0.001). This increase existed but was lower in epileptic animals, producing significant group differences in all the phases of the disease (p < 0.028). Furthermore, the quantification of the SV2A expression in vivo with the [18F]UCB-H radiotracer or ex vivo with immunofluorescence led to equivalent results, with a positive correlation between both.ConclusionsEven if further studies in humans are required, the ability to detect a progressive decrease in SV2A expression during the development of temporal lobe epilepsy supports the use of [18F]UCB-H as a useful tool to differentiate, in vivo, between healthy and epileptic animals along with the development of the epileptic disease.

Highlights

  • Worldwide, around 50 million people suffer from epilepsy, a neurological chronic disorder characterized by recurrent and unprovoked seizures [1]

  • The development and preclinical evaluation of new positron emission tomography (PET) radiotracers has provided new longitudinal insights on the neurobiological processes affected by epilepsy [4, 5]

  • We conducted, for the first time, a longitudinal in vivo evaluation of the variations of synaptic vesicle 2A (SV2A) expression associated with the development of temporal lobe epilepsy (TLE) in the kainic acid rat model

Read more

Summary

Introduction

Around 50 million people suffer from epilepsy, a neurological chronic disorder characterized by recurrent and unprovoked seizures [1]. Studying the underlying pathophysiology of this disease is essential for the discovery of more efficient treatments [2, 3]. In this regard, the development and preclinical evaluation of new positron emission tomography (PET) radiotracers has provided new longitudinal insights on the neurobiological processes affected by epilepsy [4, 5]. Two have been extensively investigated: (1) alterations in the glucose metabolism of the brain, quantified through [18F]-fluoro-2-deoxy-D-glucose ([18F]FDG) radiotracer [6, 7], and (2) neuroinflammatory processes, detected with different translocator protein (TSPO) markers [8,9,10]. Over the last few years, a third potential biomarker has drawn attention to the scientific community: (3) the determination of synaptic density through the evaluation of the synaptic vesicle 2A (SV2A) protein [11,12,13,14]

Objectives
Methods
Findings
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call